Abstract Purpose: Activating somatic mutations in the epidermal growth factor receptor (EGFR) gene are present in a small subset of lung adenocarcinomas.These mutations cluster in specific regions and confer sensitivity to inhibitors of the tyrosine kinase activity of EGFR. To further determine the genetic and molecular characteristics of tumors carrying EGFR gene mutations, we investigated the EGFR gene status in lung adenocarcinomas and evaluated its association with specific characteristics of the patients and tumors, such as mutations at KRAS and p53, EGFR and ErbB2 gene amplification, levels of EGFR and HER2 proteins, and levels of downstream effectors of EGFR, such as phospho^extracellular signal-regulated kinase and phospho-S6 proteins. Experimental Design: The mutational status of EGFR was determined by direct sequencing in 86 primary lung adenocarcinomas and12 lung cancer cell lines, and was correlated with a number of variables relating to the tumor and patient. A tissue microarray containing 37 lung tumors was constructed to determine, by fluorescence in situ hybridization analysis, the number of copies of EGFR and ErbB2 genes and, by immunohistochemistry, the levels of EGFR, HER2, phospho-ERK, and phospho-S6 proteins. Results: EGFR gene mutations were identified in 13% of the primary tumors. The type and clustering of the mutations were identical to those previously reported. Amplification of the EGFR occurred in14% of the tumors and could arise in tumors with EGFR mutations. Interestingly, mTOR activation, as measured indirectly by augmented levels of phospho-S6 protein, was more frequent in tumors with gene alterations in either EGFR or KRAS (P = 0.00005; Fisher's exact test) than in their wild-type counterparts. Conclusions: Our data agree with the accumulation of EGFR mutations in a subset of patients with lung cancer. Moreover, we report EGFR gene amplification in EGFR-mutant tumors and a positive correlation between EGFR or KRAS alterations and activation of mTOR signaling.
Non-small cell lung tumors carry many molecular abnormalities, including aberrant protein expression, gene promoter hypermethylation and gene mutations (1) . Although the levels of many proteins are aberrant in lung tumors, only a few genes exhibit genetic alterations. Recently, somatic mutations in EGFR have been identified in a subset of lung adenocarcinomas, including a new member into the small group of genes that are known to be mutated in lung cancer (2 -4) .
The epidermal growth factor receptor (EGFR, Erb-B1) belongs to the erbB family of transmembrane tyrosine kinase receptor proteins, which also includes HER2/neu (encoded by erb-B2), HER3 (encoded by erb-B3), and HER4 (encoded by erb-B4; ref. 5 ). These receptors, by binding to different ligands, trigger a cascade of intracellular signaling reactions that lead to the regulation of several aspects of cell biology, such as cell division, apoptosis, and cytoskeletal rearrangement (5) . Mutations in the EGFR gene in lung cancer lead to amino acid changes or in-frame deletions in exons 18 to 21 and arise more frequently in cases of adenocarcinomas, females, nonsmokers, and people of Asian origin (2 -4, 6, 7) . These mutations seem to enhance the ability of the ligand to induce EGFR autophosphorylation (3, 8, 9) . In addition to its role in lung carcinogenesis, the presence or absence of EGFR mutations has important clinical implications because it seems to determine the responsiveness to EGFR tyrosine kinase inhibitors such as gefitinib (Iressa, ZD1839) or erlotinib (Tarceva, OSI-774; refs. 2 -4, 10) . Furthermore, EGFR and ErbB2 gene amplification and protein overexpression have been observed in a subset of lung tumors [see ref. (11) for review]. Tumors featuring gene amplification also have concomitant protein overexpression, although the opposite is not necessarily true. Interestingly, an association between EGFR mutations and increased EGFR gene copy number has recently been described in lung adenocarcinoma cell lines, suggesting a mechanism for amplifying the effect of these oncogenic mutations (8) .
Activation of EGFR is mediated by autophosphorylation at several key tyrosine residues leading to the binding of different adaptors involved in downstream signaling (5) . The EGFR downstream pathways include AKT and RAS/extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase, which are involved in cell survival and cell proliferation, respectively. Whether any of these signal transduction pathways is a preferred target of EGFR gene mutations is currently under investigation. Several publications have reported that mutations in EGFR and KRAS, but not in p53, are mutually exclusive (6, 7, 12) . These observations may indicate that mutations at both genes are functionally equivalent, hence alterations at only one of them is enough to trigger constant activation of the signaling through RAS/ERK/mitogen-activated protein kinase. However, other studies have reported that EGFR mutants selectively activate AKT-mediated signal transduction but have no effect on ERK signaling (13) .
In this study, we have screened a set of primary lung adenocarcinomas from Spanish patients and lung cancer cell lines for EGFR mutations, and evaluated the genetic (KRAS, p53 gene mutations and EGFR, ErbB2 gene amplification) and molecular (EGFR, HER2, phospho-ERK and ribosomal phospho-S6 protein expression) context in which these mutations arise.
Materials and Methods
Patients and tumor characteristics. Tumor and matched normal tissues from 86 patients diagnosed with lung adenocarcinoma were provided by the Spanish National Cancer Centre Tumor Bank Network, Spanish National Cancer Centre (Madrid, Spain), with the collaboration of the following hospitals: Hospital Universitario 12 de Octubre and Hospital Universitario Puerta de Hierro in Madrid, Hospital Virgen de la Arrixaca in Murcia and Hospital Virgen de la Salud, in Toledo. There were 30 and 56 females and males, respectively, and the median age was 60 years; 71 and 15 were fresh-frozen and paraffin-embedded tumors, respectively. Available slides were reviewed by two pathologists (E. Conde and F. Lopez-Rios) and was classified according to WHO criteria (14) . Informed consent was obtained from each patient.
DNA extraction and mutation analysis. Representative sections from tissue used for DNA extraction were stained with H&E. Freshly frozen and paraffin-embedded tissue from tumors was meticulously dissected to ensure that specimens contained at least 70% tumor cells. Approximately 10 to 20 Am sections were collected from normal and tumor samples and placed in 1% SDS/proteinase K (10 mg/mL) at 58jC overnight. Digested tissue was then subjected to phenolchloroform extraction and ethanol precipitation. The cell lines A427, A549, H23, H661, H1155, H1170, H1299, H1395, H2087, H2126, Calu-3, and U1552 were obtained from the American Type Culture Collection (Rockville, MD), and cultured under the recommended conditions. DNA from cell lines was extracted using standard proteinase K/isoamyl alcohol protocols. For the screening of EGFR gene mutations, exons 18 to 21 of the gene were PCR-amplified and automatically sequenced. For frozen tumors, PCR reactions were done in a total volume of 25 AL. The mix contained 1.25 units of DNA polymerase (Biotools, Madrid, Spain), 2.5 AL of Tth buffer 10Â (Biotools), 2 mmol/L of MgCl 2 , 200 Amol/L of each deoxynucleotide, 2 AL of DMSO, 6 ng/AL of each primer, and 50 ng of genomic DNA. The PCR cycling conditions consisted of an initial denaturation at 94jC for 5 minutes, followed by two cycles of denaturation (30 seconds at 94jC), annealing (1 minute at 60jC), elongation (1 minute at 72jC), followed by 35 cycles of denaturation (30 seconds at 94jC), annealing (1 minute at 58jC), and elongation (1 minute at 72jC). After the last cycle, a final extension (1 minute at 72jC) was added. The primers used for PCR were as follows: exon 18, forward 5V -TCCAAATGAGCTGG-CAAGTG-3V and reverse 5V -CAAACACTCAGTGAAACAAAGAG-3V ; exon 19, forward 5V-TGCATCGCTGGTAACATCC-3V and reverse 5V -TGGAGA-TGAGCAGGGTCTAG-3V ; exon 20, forward 5V -GATCGCATTCATGC-GTCTTC-3V and reverse 5V -TCCCCATGGCAAACTCTTGC-3V ; exon 21, forward 5V -GCTCAGAGCCTGGCATGAA-3V and reverse 5V -GCATCCTC-CCCTGCATGTG-3V. The following were used for the sequencing reaction: exon 18, 5V -AAATGAGCTGGCAAGTGCCG-3V ; exon 19, 5V-CA-TCGCTGGTAACATCCACC-3V; exon 20, 5V -CGCATTCATGCGTCTTC-ACC-3V ; and exon 21, 5V-CAGAGCCTGGCATGAACAT-3V .
For paraffin-embedded tumors, PCR reactions were done in a total volume of 25 AL. The mix contained: 21. ng/AL of each primer, 100 ng of genomic DNA. Thermal cycling conditions for exons 19 and 21 included 5 minutes at 94jC, followed by two cycles of 94jC for 30 seconds, 58jC for 1 minute, 72jC for 1 minute, and 40 cycles of 94jC for 30 seconds, 56jC for 1 minute, 72jC for 1 minute, and finally one cycle of 72jC for 1 minute; and for exons 18 and 20, 5 minutes at 94jC, followed by two cycles of 94jC for 30 seconds, 60jC for 1 minute, 72jC for 1 minute, and 40 cycles of 94jC for 30 seconds, 58jC for 1 minute, 72jC for 1 minute, and finally one cycle of 72jC for 1 minute. The primers used for PCR were as follows: exon 18, forward 5V -TGACCCTTGTCTCTGTGTTC-3V and reverse 5V -AG-AGGCCTGTGCCAGGGAC-3V ; exon 19, forward 5V-CAGTTAACGT-CTTCCTTCTC-3V and reverse 5V -CACACAGCAAAGCAGAAACTC-3V ; exon 20, forward 5V -ACTGACGTGCCTCTCCCTC-3V and reverse 5V -CCC-GTATCTCCCTTCCCTG-3V ; exon 21, forward 5V -TCACAGCAGG-GTCTTCTCTG-3V and reverse 5V -CTGACCTAAAGCCACCTCC-3V . The following were used for the sequencing reaction: exon 18, 5V -CCCT-TGTCTCTGTGTTCTTG 3V ; exon 19, 5V -GTTAACGTCTTCCTTCTCTC-3V; exon 20, 5V -CTGACGTGCCTCTCCCTCC-3V; and exon 21, 5V -AGCAG-GGTCTTCTCTGTTTC-3V .
The PCR products were electrophoresed on 2% agarose gel and stained with ethidium bromide. The bands were excised, purified with an UltraClean 15 Kit (MO Bio Laboratories, Solana Beach, CA) and sequenced using Big Dye Terminator chemistry (Applied Biosystems, Foster City, CA) with an ABI PRISM 3700 DNA Analyzer (Perkin-Elmer Life Sciences, Inc., Boston, MA). All variants were confirmed by resequencing independent PCR products. Mutations in p53 and KRAS genes were screened as previously described (15) .
Tissue microarray. Formalin-fixed, paraffin-embedded tissue blocks from 37 patients were used for tissue microarray construction. A tissue arrayer (Beecher Instruments, Silver Spring, MD) was used to construct the tissue microarray (16) . Slides were reviewed by pathologists (E. Conde and F. Lopez-Rios), who selected areas containing tumor cells, avoiding those areas featuring necrosis, inflammation and keratinization. To assess reproducibility, we selected two 1-mm diameter cylinders from different areas of the tumor. Normal lung tissue and reactive tonsil tissue were included as control specimens to ensure quality, reproducibility, and homogenous staining.
Fluorescence in situ hybridization analysis. Fluorescence in situ hybridization analysis was carried out for the detection of ErbB2 and EGFR amplification using commercially available probes from Vysis, Inc. (Downers Grove, IL). We used 4-Am sections of all the tissue microarrays. In both cases, the specified gene probes, which span the entire gene, were labeled in SpectrumOrange. These probes also contain a centromeric probe for chromosome 7 (for the EGFR probe) and chromosome 17 (for the ErbB2 probe), which are labeled in SpectrumGreen and hybridize to the alpha satellite DNA located at their centromeres.
The slides were deparaffinized, boiled in a pressure cooker with 1 mmol/L EDTA (pH 8.0) for 10 minutes, and incubated with pepsin at 37jC for 30 minutes. The slides were then dehydrated. The probes were denatured at 75jC for 2 minutes after overnight hybridization at 37jC in a humid chamber. Slides were washed with 0.4Â SSC and 0.3% NP40.
Fluorescence in situ hybridization was evaluated without previous knowledge of other genetic, clinical, or immunohistochemical results. Fluorescence signals in each sample were scored by counting the number of single-copy gene and centromeric signals in an average of 130 (60-210) well-defined nuclei. Amplification was defined as the presence (in >5% of tumor cells) of either >10 gene signals or more than three times as many gene signals as centromere signals in the same chromosome. The cutoff values for copy-number changes were obtained from the analysis of normal adjacent cells in each experiment.
Immunohistochemistry. Immunohistochemical staining of EGFR, HER2, phospho-ERK, and phospho-S6 (phospho-Ser 235/236 ) proteins was done on 3-Am-thick sections from the tissue microarray and transferred to silanized glass slides. The protocols used were those previously described (16) . After incubation, immunodetection was done with the DAKO EnVision Visualization Method (Dako, Glostrup, Denmark), with diaminobenzidine chromogen as the substrate. Sections were counterstained with hematoxylin. The antibodies used in the analyses, indicating source, dilution, and corresponding internal controls are described in Table 1 . Immunostaining was evaluated by two different pathologists (E. Conde and F. Lopez-Rios), using uniform criteria and without prior knowledge of the clinical and pathologic characteristics of the patients.
The following criteria were used for individual evaluation of the immunostaining:
EGFR immunostaining was scored as positive (or 1) and negative (or 0) when z10% and <10% of tumor cells, respectively, showed unequivocal membrane staining (17, 18) . Basal cells, in the normal respiratory epithelium, showed immunoreactivity and were used as an internal positive control. The alveolar epithelium was used as an internal negative control. HER2 immunostaining was scored using the HercepTest scoring system. No staining or membrane staining in <10% of tumor cells were scored as 0; weak membrane staining in >10% of tumor cells or cells with incomplete membrane staining were scored as 1+; weak/moderate complete membrane staining in >10% was scored as 2+; strong, complete membrane staining in >10% of tumor cells was scored 3+. Scores of 2+ and 3+ were judged as positive, whereas scores of 0 or 1+ were considered negative. Appropriate positive and negative controls were included (19) . Phospho-ERK immunostaining was scored as positive (or 1) and negative (or 0) when z15% and <15% of the cells, respectively, were immunoreactive. Specimens were also scored according to the location of the staining (nuclear and/or cytoplasmic). Endothelial cells were used as internal positive controls. Normal lung tissue was used as an internal negative control (20) .
Phospho-S6 staining was scored as negative (or 0); weak cytoplasmic positive staining (or 1); moderate cytoplasmic positive staining (or 2) and strong cytoplasmic positive staining (or 3). Extent of staining was scored as 0 (0%), 1 (V50%), 2 (51-75%), 3 (76-85%), and 4 (>85%) according to the percentage of tumor cells that were immunoreactive. The sum of the intensity and extent of scoring was used as the final staining score (0-7). Tumors with a final score of z5 were considered positive or high-intensity, whereas those with a final score of <5 were negative or low-intensity. Endothelial cells and lymphocytes were used as internal positive and negative controls, respectively. In normal respiratory epithelium, weak to moderate phospho-S6 reactivity was detected in the cytoplasm of all layers. The alveolar epithelium also showed weak/medium immunoreactivity for phospho-S6 (21).
Statistical analysis. Frequencies were compared either by Fisher's exact test or the m 2 contingency test, as appropriate. Differences of P < 0.05 were considered statistically significant. Analyses were carried out with the SSPS program, version 10.0.5 (SSPS Inc., Chicago, IL).
Results
EGFR gene mutations in lung adenocarcinomas: genetic and pathologic context. Tumor DNA from 86 unselected lung adenocarcinoma patients was screened for mutations within exons 18 to 21 of the EGFR gene. Eleven (13%) somatic mutations were identified. All of them were previously described changes, either amino acid substitutions in exon 21 or in-frame deletions in exon 19 ( Table 2 ). Examples of some of these alterations are shown in Fig. 1A-B . In addition to primary tumors, 12 lung adenocarcinoma cell lines (A427, A549, H23, H661, H1155, H1170, H1299, H1395, H2087, H2126, Calu-3, and U1552) were tested, but showed no mutations. Other variants that did not lead to amino acid changes and were confirmed to be germ line polymorphisms are also listed.
As indicated in Table 3 , EGFR mutations were more common in females and in nonsmokers (P < 0.05). Among the 47 cases available for reevaluation of histology according the most recent WHO classification (14) , there were 7 mutated and 40 nonmutated cases. Of those seven adenocarcinomas mixed subtypes harboring EGFR mutations, five exhibited prominent bronchioloalveolar features (AD-BAC), one had a conspicuous papillary (AD-PP) pattern and the remaining tumor was a poorly differentiated adenocarcinoma. Among those 40 reviewed adenocarcinomas without EGFR mutations, 20 (50%) were well-differentiated adenocarcinomas (including five with AD-BAC and one with a predominant papillary pattern). No pure BACs were observed in either group. None of the tumors carrying EGFR mutations had concomitant KRAS 
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on January 13, 2018. © 2006 American Association for clincancerres.aacrjournals.org Downloaded from tumors and appropriate controls. The 28 EGFR wild-type tumors were chosen arbitrarily from our set of tumor specimens. First, we used fluorescence in situ hybridization analysis to assess the EGFR and ErbB2 gene copy number. Only 2 of the 35 analyzable (6%) tumors featured ErbB2 gene amplification (>10 copies). This alteration occurred in a background of wildtype EGFR and KRAS, but in mutant p53. Conversely, high levels of EGFR gene amplification (copy numbers from 5 to 15) were observed in 5 (14%) of the 35 tumors. None of these featured simultaneous KRAS mutations or ErbB2 gene amplification, but three tumors had concomitant mutant EGFR. Based solely on the appearance of the electropherograms, EGFR gene amplification seemed to target the mutant allele specifically in one case, as depicted in Fig. 1C . This tumor had a mutation in exon 19 and showed only traces of the wild-type allele, implying that EGFR gene amplification targeted the mutant allele. In contrast, the other two cases featured a mutation in exon 21 but also a strong contamination of the normal allele, probably due to gene amplification of the wildtype allele. To determine whether gene amplification and EGFR gene mutations lead to increased protein levels, we performed immunohistochemistry for EGFR and HER2 proteins. Following previously described criteria, EGFR and HER2 immunostaining was categorized as 0 (or negative) and 1 (or positive) as indicated in Materials and Methods. According to these criteria, 22 (63%) and 13 (37%) of the tumors were classified as negative and positive for EGFR protein, respectively. Two tumors were not available for analysis. Positive EGFR immunostaining was more common in EGFR mutant than in wildtype tumors (4 of 9, 44% versus 9 of 28, 32%), respectively, although the numbers were not sufficient to allow definite conclusions to be drawn. All tumors with increased EGFR gene copy numbers were also positive for EGFR immunostaining (Fig. 1D) . Table 4 summarizes the data on EGFR gene copy number and protein levels of EGFR mutant tumors. On the other hand, 32 (86%) of the tumors were negative and 5 (13%) were positive for HER2 immunostaining. This latter category includes tumors scored as 2+ (four tumors) and 3+ (one tumor). ErbB2 gene amplification was detected in two primary lung adenocarcinomas, one of them with the highest level (3+) and the other with level 2+ of HER2 protein staining. Both featured wild-type EGFR and KRAS genes. Levels of phosphorylation of ERK (phospho-ERK) and ribosomal protein S6 (phospho-S6) in lung primary adenocarcinomas according to EGFR gene status. To determine whether EGFR mutations lead to constitutive activation of downstream targets, we measured the levels of phosphorylation of ERK and S6 proteins in tumors included in the tissue microarray. Phospho-ERK mediates the RAF/MAP/ERK kinase signaling pathway, whereas phosphorylation of S6 protein was used as a surrogate marker for measuring S6K and mTOR activity. Examples of phospho-ERK and phospho-S6 immunostaining are depicted in Fig. 2A . Eight (22%) and 28 (78%) of the 36 lung primary tumors analyzed were positive and negative for phospho-ERK immunostaining, respectively. The frequency of positive immunostaining for phospho-ERK was similar among tumors carrying mutations in EGFR or KRAS as in the wild-type genes. On the other hand, most tumors were positive for phospho-S6 immunostaining. However, according to the criteria described in Materials and Methods, 20 (54%) and 17 (46%) of the 37 tumors had high and low levels of phospho-S6 immunostaining, respectively. Interestingly, most EGFR-mutant tumors had high levels of phospho-S6 protein relative to EGFR wild-type (8 of 9, 89%, compared with 12 of 28, 43%; P = 0.02; Fisher's exact test). We then compared the levels of these proteins in tumors carrying genetic alterations at either EGFR and KRAS and wild-type tumors. Remarkably, we observed that, in the former group, increased levels of phospho-S6 were present in 16 of 18 tumors (89%), significantly more than in the latter group (4 of 19 tumors, 21%; P = 0.00005; Fisher's exact test; Fig. 2B ).
Discussion
The recent identification of activating somatic mutations in the EGFR gene in lung adenocarcinomas and their proposed relevance in predicting the response to tyrosine kinase inhibitors of EGFR have had a significant effect in the field of lung cancer treatment (2 -4) . It is now critical to focus on unraveling the mechanisms and characteristics underlying the presence of EGFR mutations. In the present study, we have found a frequency of EGFR gene mutations in lung adenocarcinomas of Spanish patients similar to that reported for patients of Caucasian origin, and slightly lower than that of patients of Asian origin (6, 7, 22) . Our observations support previous results on the clustering of these mutations in individuals who have never used tobacco and whose tumors are classified as adenocarcinomas with bronchioloalveolar features (BAC; refs. 4, 6, 23) . Regarding the latter, it was previously known that the presence of BAC or papillary features were significant predictors of the response to tyrosine kinase inhibitors in lung adenocarcinomas, (24, 25) . More recent reports proposed that the pathologic features of tyrosine kinase inhibitor responders overlaps with those of terminal respiratory unit adenocarcinoma (23) , which according to the WHO classification includes most nonmucinous BAC, most of the adenocarcinomas mixed subtype with BAC features and a subset of papillary carcinomas (14) . However, given the lack of consensus in the use of the term ''BAC'' versus ''adenocarcinoma'' it is extremely difficult to compare published reports.
The activation of the tyrosine kinase activity of EGFR or HER2 switches on intracellular signaling cascades that include the ras/MAP signal transducers (5). We observed a lack of simultaneous mutations at EGFR and KRAS genes, which is consistent with the widely accepted hypothesis that only one component of a cancer pathway needs to be genetically inactivated/activated for neoplastic clonal expansion to occur and with previously published data (6, 12) . On the other hand, although p53 and EGFR mutations frequently coexisted in the same tumor specimen, here we confirmed previous observations on the low frequency of G:C-to-T:A transversions in the p53 gene in EGFR-mutant tumors (6) . Because these types of p53 mutations are typically associated with tobacco carcinogens (26), our observations are further evidence of the biological relevance of EGFR mutations in non -tobacco-related lung adenocarcinomas.
EGFR gene amplification is also present in a subset of lung tumors (27, 28) . Our data imply that EGFR amplification is always accompanied by increased protein expression and that this prevails in tumors carrying EGFR mutations. The biological significance of the coexistence of EGFR mutations and gene amplification in the same tumor specimen is not obvious. Because of the large number of extra copies, amplification of EGFR gene in lung tumors is unlikely to arise stochastically and should confer a growth advantage on the tumor cell, even in the presence of gene mutations. An important question requiring an answer is whether there is selective amplification of the mutant or wild-type allele. Previous investigations reported only EGFR mutant bands in the chromatograms in some lung primary tumors and cell lines, without a detectable background of normal DNA (4, 6) . This is especially intriguing in primary tumors in which contamination with normal stromal cells is unavoidable. Several mechanisms, including gene amplification of the mutant allele and loss of the wild-type allele, have been proposed (6, 12, 29) . For example, in one of the largest series to date, 40% of the electropherograms suggested amplification of the mutant allele (12) . Our present data support the hypothesis that gene amplification of the mutant allele is the most plausible explanation for these observations. However, and although interpreted solely on the basis of DNA sequencing, the mutant allele did not always seem to be the target of EGFR amplification. Regardless of the biological significance, these observations raise concerns about the masking effect that gene amplification of the wild-type allele might have in the detection of EGFR gene mutations and so in the identification of patients who might benefit from tyrosine kinase inhibitor treatments. In this regard, it is interesting to note that high EGFR gene copy number has been recently proposed as a predictor for gefitinib efficacy (28, 30, 31) .
Finally, we observed that, unlike in their wild-type counterparts, lung adenocarcinomas carrying activating gene alterations in EGFR or KRAS have higher levels of phospho-S6, a ribosomal protein that is phosphorylated by the mTORsubstrate, S6 kinase. Our present data confirm, in primary tumors, recent observations that the phosphoinositide-3-kinase/AKT/mTOR pathway can mediate signaling of tyrosine kinase receptors, also via RAS, and that RAS plays a critical role in activating mTOR in both normal and tumorigenic settings (32) .
On the other hand, increased levels of phopsho-AKT protein have been proposed as a marker of gefitinib sensitivity (28, 33) , although no significant correlation has been observed between the presence of EGFR mutations and phospho-AKT overexpression (33) . Following this line of reasoning and taking into account that 40% to 90% of adenocarcinomas may contain areas of BAC (25) , phospho-S6 immunohistochemistry may prove useful to select tumors for EGFR mutation testing.
In conclusion, we have further determined the genetic and molecular context in which EGFR mutations arise, which helps to elucidate their biological role and provides additional information for the selection of patients who could be candidates for EGFR mutation analysis.
